




December 5, 2016 
New information is presented in dark red. 
1. Zika Virus 
Zika virus is a mosquito-borne flavivirus (in the same family as yellow fever, dengue and West Nile viruses) 
previously found largely in Africa and Southeast Asia. Since 2015, evidence of active transmission of Zika virus 
has been found in other parts of the world. Surveillance for transmission is ongoing and the most current 
information about areas with Zika transmission can be found at http://www.cdc.gov/zika/geo/index.html.  Zika 
virus infections continue to be reported in travelers returning to the United States from other countries with 
some limited local transmission reported in parts of Florida. 
An estimated 80% of persons infected with Zika virus are asymptomatic. In symptomatic infection, the 
incubation period is 3-12 days.  Symptomatic disease is generally mild and characterized by at least two of the 
following: 
 acute onset of fever;  
 maculopapular rash which may be pruritic; 
 arthralgia; or  
 nonpurulent conjunctivitis.  
Symptoms usually last from several days to 1 week. Severe disease requiring hospitalization is uncommon, 
and fatalities are rare.  
The most significant concern associated with Zika virus infection is for pregnant women. In pregnant 
women who become infected with Zika virus, it is possible for the virus to spread to and through the placenta to 
the developing fetus. When this happens, it can result in complications of pregnancy and birth defects. The 
complete range of possible adverse birth outcomes associated with Zika virus infection is unknown at this time 
but has included: microcephaly; intracranial calcifications; ventriculomegaly; arthrogryposis; abnormalities of 
the corpus callosum, cerebrum or cerebellum; fetal loss; and abnormalities in both vision and hearing in the 
neonate. Pregnant women can be infected with Zika virus in any trimester. No evidence exists to suggest that 
pregnant women are more susceptible to Zika virus infection or experience more severe disease during 
pregnancy, though some evidence indicates that prolonged maternal viremia can occur during pregnancy. 
Maternal-fetal transmission of Zika virus has been documented throughout pregnancy; some evidence exists 
that infection during the first trimester results in the most significant risk to the fetus.  
In addition, small numbers of patients have been diagnosed with Guillain-Barré syndrome, 
meningoencephalitis and thrombocytopenia following Zika virus infection. 
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 2. Planning Travel to an Area with a Zika Virus Outbreak 
Because there is neither a vaccine nor prophylactic medications available to prevent Zika virus infection, the 
Centers for Disease Control and Prevention (CDC) and the Massachusetts Department of Public Health 
(MDPH) continue to recommend that all pregnant women, and those planning on becoming pregnant 
within two months, postpone travel to areas with Zika virus outbreaks. Because sexual transmission is 
possible, the male sex partners of women who are pregnant or planning on attempting conception 
within six months, should also strongly consider postponing their travel. 
If a pregnant woman, a woman who wishes to become pregnant, or the sex partner of these women, must 
travel to an area with Zika virus transmission, they should be counseled that this poses a risk to the unborn 
child; for couples trying to become pregnant, this travel will result in a recommendation to delay conception. All 
of these individuals must be advised to strictly follow steps to avoid mosquito bites. Mosquitoes that spread 
Zika virus bite both indoors and outdoors, mostly during the daytime; therefore, it is important to ensure 
protection from mosquitoes throughout the entire day. Mosquito prevention strategies, recommended for all 
travelers to an area with transmission, include: 
 wearing long-sleeved shirts and long pants; 
 using U.S. Environmental Protection Agency (EPA)–registered insect repellents;  
 using permethrin-treated clothing and gear; and  
 staying and sleeping in screened-in or air-conditioned rooms.  
 
When used as directed on the product label, insect repellents containing DEET, picaridin, and IR3535 are safe 
for pregnant women.  
3. Recommendations about Preventing Sexual Transmission, especially to Pregnant Women, and 
Delaying Conception for Individuals or Couples with Recent Travel to an Area with a  Zika Virus 
Outbreak 
Sexual transmission of Zika virus from both infected men and women to their sex partner is possible. Evidence 
of Zika virus has been found in semen for up to 93 days after symptom onset and in vaginal fluids up to 11 
days. It is not known how frequently Zika virus is found in semen or vaginal fluids or how long it might persist.  
Preventing Sexual Transmission to Pregnant Women: individuals who reside in or have traveled to an area 
with a Zika virus outbreak who have a pregnant partner should: 
 abstain from sex; or  
 consistently and correctly use latex condoms every time they have sex* for the duration of the 
pregnancy.  
*Sex includes vaginal, anal and oral sex, as well as the sharing of sex toys.  
Preventing Sexual Transmission and Delaying Conception for Non-Pregnant Couples 
Women with possible Zika virus exposure should use condoms or abstain from sex AND delay 
conception for at least 8 weeks after start of symptoms or last possible exposure. 
Men with possible Zika virus exposure should use condoms or abstain from sex AND delay conception 
at least 6 months after start of symptoms or last possible exposure. 
 
Fact sheets on condoms and information on using condoms correctly are available from the U.S. Department 
of Health and Human Services and CDC at https://www.aids.gov/hiv-aids-basics/prevention/reduce-your-
risk/using-condoms/ and http://www.cdc.gov/condomeffectiveness/brief.html#Condom. 
 
 
 4. Understanding Laboratory Testing for Zika Virus 
Two types of laboratory tests are available to assess infection with, or evidence of exposure to, Zika virus.  
1. RT-PCR detection of Zika virus RNA indicates the presence of the virus itself. PCR for Zika RNA can 
be done on serum, urine, cerebral spinal fluid, and amniotic fluid. Whole blood has recently been added 
as a suitable test specimen in certain situations. Although Zika virus RNA is generally only found in 
serum for 3-4 days, there have been instances of prolonged viremia (up to 10 weeks) in pregnant 
women. Evidence of Zika virus RNA in urine may also be prolonged following symptom onset or 
exposure. Approval requirements, sample types and timing of collections for at-risk patients are 
detailed in the Diagnostic Testing Guidance table. This test is available at the MA SPHL for all listed 
sample types. 
2. Anti-Zika virus IgM antibodies provide evidence of recent exposure in patients meeting the designated 
testing criteria. Testing to detect anti-Zika virus IgM antibodies can be performed on serum samples 
from potentially exposed, symptomatic or asymptomatic patients as detailed in the Diagnostic Testing 
Guidance table. Anti-Zika virus IgM antibodies reliably appear within 2 weeks following exposure and 
can last up to 12 weeks. This test is available at the MA SPHL. Serum samples with a positive or 
equivocal anti-Zika virus IgM result must be confirmed by testing serum for the presence of neutralizing 
antibodies using the plaque reduction neutralization test (PRNT). This test is available at the MA SPHL.  
In most instances, detection of Zika virus RNA using RT-PCR on samples of serum and urine, early in 
infection, is optimal to confirm infection with Zika virus. However, the most appropriate application of this test 
requires that the patient has been currently, or very recently, symptomatic with clinically consistent Zika-like 
disease. Unfortunately, 80% of individuals exposed to Zika virus remain asymptomatic making this type of 
laboratory test less suitable because the likely viremic period of the patient cannot be determined.  
In many cases, serological testing is the most appropriate diagnostic tool. Interpretation of serology tests may 
be complicated due to recent and/or prior exposure to another cross-reacting flavivirus (especially dengue 
virus), or a vaccination history with other flaviviruses such as yellow fever or Japanese encephalitis. Due to the 
extensive cross-reactivity of Zika and dengue viruses, and the persistence of both dengue and chikungunya 
viruses in areas with Zika virus transmission, additional testing for these other diseases may be required. 
Despite testing for additional viruses, in many cases, a positive Zika virus IgM from a single serum with 
laboratory evidence of neutralizing antibody in both the Zika and dengue PRNT assays will be indicative of 
“recent exposure to a flavivirus” and a definitive diagnosis may not be possible.  
Selection and interpretation of the appropriate test by the MA SPHL requires specific clinical 
information including dates and location of travel, evidence of mosquito exposure, symptoms clinically 
consistent with Zika virus, date of symptom onset, and any previous exposure to dengue virus, yellow 
fever vaccine or Japanese encephalitis vaccine. This information must be provided when calling for 
testing approval AND on the specimen submission form that must accompany the sample.  
 
5. Availability of Laboratory Testing for Zika Virus 
 
In order to ensure comprehensive testing for high risk patients, all samples from pregnant women with 
potential exposure to Zika virus should be sent to the MA SPHL. Commercial laboratory testing might 
be an alternative, but ONLY for individuals who do not meet the criteria for testing at MA SPHL as 
detailed in the Diagnostic Testing Guidance table, and only if the appropriate test is ordered based on 
presence/absence of symptoms and on the timing of specimen collection relative to disease onset or 
last date of possible exposure. 
 
 The table below provides additional information about the types of laboratory testing for Zika virus and where 
they are currently available. Sample submission should not be based on this information. Specific guidance for 
individual circumstances is available below in the Diagnostic Testing Guidance table. 
 
Test Type Symptoms? Sample types Availability Turn-around Time 




●  MA SPHL              
●  Commercially  
available 
MA SPHL < 7 days 
after sample receipt 
Symptomatic urine 
●  MA SPHL              
●  Commercially  
available 
MA SPHL < 7 days 
after sample receipt 
N/A amniotic fluid MA SPHL 
MA SPHL < 7 days 
after sample receipt 
 
Symptomatic CSF MA SPHL MA SPHL < 7 days after sample receipt 
IgM MAC-ELISA 







●  MA SPHL             
●  Commercially  
available 
MA SPHL < 7 days 
after sample receipt 
Plaque reduction 
neutralization test 








●  MA SPHL              
●  CDC 
  
MA SPHL < 3 weeks 
after sample receipt 
CDC – longer than 3 
weeks 
6. Diagnostic Testing Guidance Tables 
To discuss/request testing, please contact the MDPH Epidemiology Line at 617-983-6800, available 24/7. If the 
testing requested meets the current guidelines, testing will be approved. The information requested below 
MUST accompany the sample(s) either on the specimen submission form or on an attached form. Samples 
that do not meet the criteria or do not include all the requested information will be rejected for testing. 
When contacting the MDPH, please have the following information available: 
 Date of onset of disease symptoms; 
 Date of specimen collection; 
 Unusual immunological status of patient (e.g., immunosuppression); 
 Travel history with dates (e.g., travel to area with current transmission 
http://www.cdc.gov/zika/geo/index.htm); 
 Vaccination history (e.g., vaccination against yellow fever, Japanese encephalitis); 
 Disease history (e.g., previous history of chikungunya or dengue fever); and 
 Brief clinical summary including suspected diagnosis and approximate gestational age 
 
Approved specimens should be submitted using the MA SPHL clinical specimen submission form 
(http://www.mass.gov/eohhs/docs/dph/laboratory-sciences/general-submission-form.pdf) and should include 
the information provided above for consistency. 
Specific information on specimen collection, storage and shipping is available on the companion 
document, “Specimen Collection, Storage and Shipment for Molecular and Serological Testing for Zika 


































































































































































































































































































































 7. ADDITIONAL RESOURCES 
CDC Zika virus web site: http://www.cdc.gov/zika/index.html 
All Areas with Active Zika Virus Transmission 
Caring for Pregnant Women and those of Reproductive Age 
 UPDATE: Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible 
Zika Virus Exposure — United States, July 2016 | MMWR (July 29, 2016) 
 Webpage: Clinical Guidance for Healthcare Providers Caring for Pregnant Women and Women of 
Reproductive Age with Possible Zika Virus Exposure 
Caring for Infants and Children 
 Interim Guidelines for Healthcare Providers Caring for Infants and Children with Possible Zika Virus 
Infection – United States, February 2016 (Feb. 26, 2016) 
 Interim Guidelines for the Evaluation and Testing of Infants with Possible Congenital Zika Virus 
Infection — United States 2016 (January 29, 2016) 
 Webpage: Clinical Guidance for Healthcare Providers Caring for Infants and Children with Possible 
Zika Virus Infection 
Preventing Sexual Transmission 
 UPDATE: Update: Interim Guidance for Prevention of Sexual Transmission of Zika Virus — United 
States, July 2016 | MMWR (July 29, 2016) 
 Webpage: Zika and Sexual Transmission  
 Guidance for U.S. Laboratories Testing for Zika Virus Infection (July 26, 2016) 
Occupational Health and Safety for Healthcare Providers During Delivery 
 Preventing Transmission of Zika Virus in Labor and Delivery Settings Through Implementation of Standard 
Precautions — United States, 2016 (March 25, 2016) 
 
